THE ROAD TO LASTING RESULTS

REAL PATIENTS SHARE THEIR STORIES ABOUT MODERATE-TO-SEVERE PLAQUE PSORIASIS AND ILUMYA®

What is ILUMYA?

ILUMYA® (tildrakizumab-asmn) is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy (treatment using ultraviolet or UV light).

SELECTED IMPORTANT SAFETY INFORMATION

ILUMYA is not for everyone, only your doctor can determine if it's right for you. Do not take ILUMYA if you are allergic to ILUMYA or any of its ingredients. ILUMYA may lower your ability to fight infections and may increase your risk of infections. Before starting treatment, your doctor should check you for tuberculosis and infections.

Please read the Important Safety Information on pages 22 and 23 of this brochure and the enclosed full Prescribing Information and Medication Guide.

Visit ILUMYA.com for more information.

ILUMYA®
tildrakizumab-asmn
Injection 100 mg/mL

THE ROAD TO LASTING RESULTS

What is ILUMYA?

ILUMYA® (tildrakizumab-asmn) is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy (treatment using ultraviolet or UV light).

SELECTED IMPORTANT SAFETY INFORMATION

ILUMYA is not for everyone, only your doctor can determine if it's right for you. Do not take ILUMYA if you are allergic to ILUMYA or any of its ingredients. ILUMYA may lower your ability to fight infections and may increase your risk of infections. Before starting treatment, your doctor should check you for tuberculosis and infections.

Please read the Important Safety Information on pages 22 and 23 of this brochure and the enclosed full Prescribing Information and Medication Guide.

Visit ILUMYA.com for more information.

ILUMYA®
tildrakizumab-asmn
Injection 100 mg/mL

"After struggling with my skin for so long, feeling happy about my skin is a big deal and immeasurable."

Individual results may vary.

Holly C., 43
Started ILUMYA® (tildrakizumab-asmn) in June 2020

REAL PATIENTS, REAL TALES OF TRIUMPH

Our patients have amazing stories

Many have struggled with their moderate-to-severe plaque psoriasis for years. They've tried different treatments—topicals, pills, and other biologics. The treatments either didn't work or worked for a little while before quitting on them. That is, until they found ILUMYA®. Now, meet some real ILUMYA® patients who have faced the challenges of living with their symptoms and finally triumphed over their condition with the help of a treatment that goes the distance.

ILUMYA® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy (treatment using ultraviolet or UV light).

ILUMYA® IS A TREATMENT THAT'S IN IT FOR THE LONG HAUL*

ILUMYA® is a biologic treatment used for moderate-to-severe plaque psoriasis

From a robust patient support program to how the treatment actually works, ILUMYA® (tildrakizumab-asmn) may help you find lasting results.

*Based on 5-year data.

LASTING RESULTS

Most patients see results after just 2 doses of ILUMYA®. And 5 years into treatment, ILUMYA® is still going strong.

WORKS AT THE SOURCE

ILUMYA® works to balance the immune system from the inside out.

DOSING ADVANTAGE

Patients receive 4 doses a year after 2 starter doses.

FINANCIAL SUPPORT

ILUMYA® provides low- or no-cost options based on the type of insurance you have.

"IF I HAD TO DO IT ALL AGAIN, I DON'T THINK I COULD FIND ANYTHING BETTER."

Individual results may vary.

Mike Q., 72
Started ILUMYA® in April 2019

**Many patients wish they'd found a lasting treatment sooner.
Could ILUMYA® be the right treatment for you?
Talk to your dermatologist today.**

The most common (≥1%) adverse reactions for ILUMYA® compared to placebo are upper respiratory infections (14% vs 12%), injection site reactions (3% vs 2%), and diarrhea (2% vs 1%).



WHAT IS PLAQUE PSORIASIS?

While no one knows the exact cause of plaque psoriasis, scientists do know that it is an autoimmune disease. This means that your immune system, which usually protects your body from getting sick, mistakenly attacks healthy tissue, causing the plaques, redness, and flakes you can see on your skin.

Plaque psoriasis can be passed down from generation to generation. It can also be triggered by things we experience in everyday life, like stress, injuries, certain medications, and even foods that we eat.

68%

of patients said their "psoriasis symptoms [were] debilitating."

The invisible impact of plaque psoriasis

Before finding lasting relief with ILUMYA®, many of our patients shared that the condition had more than just physical effects on their lives. In fact, 68% said their "psoriasis symptoms [were] debilitating." Some were constantly worried about leaving flakes behind in public, while others were unable to leave the house much at all.

found a cool new dive spot

Making sense of the treatment options

With so many medicines available for treatment, you may be wondering which approach is best. Make sure to talk with your dermatologist about your treatment options and ask if ILUMYA® (tildrakizumab-asmn) can give you the long-lasting results you've been waiting for.

TOPICALS

Topical medicines are treatments applied directly to your skin, like creams and ointments. They're usually one of the first medicines people try after they're diagnosed with plaque psoriasis.

PHOTOTHERAPY

Phototherapy is also called light therapy. With phototherapy, areas of skin affected by plaque psoriasis are repeatedly exposed to ultraviolet (UV) light.

ORAL TREATMENTS

Oral treatments are prescription pills that are sometimes called systemic treatments because they work throughout the body to fight plaque psoriasis.

BIOLOGIC MEDICINES

Biologic medicines are made using natural, living sources, such as human, plant, or animal cells. Biologics target a specific part of the immune system—rather than all of it—to block only the molecules that make psoriasis worse.

ILUMYA® IS A DIFFERENT TYPE OF BIOLOGIC MEDICINE

ILUMYA® is an advanced biologic medicine. It blocks the IL-23 molecule, which is part of your immune system. IL-23 molecules become overactive if you have moderate-to-severe plaque psoriasis. This can wreak havoc under your skin, resulting in redness and plaques.

ILUMYA® works within the body to help those IL-23 molecules get back in rhythm, which means you can get your symptoms under control and keep them under control.

Already have experience using ILUMYA®? Share your story at ILUMYA.com/your-story

The most common (≥1%) adverse reactions for ILUMYA® compared to placebo are upper respiratory infections (14% vs 12%), injection site reactions (3% vs 2%), and diarrhea (2% vs 1%).

"Socializing became extremely difficult for me because my plaques made me feel so gross."

Individual results may vary.

Corey S., 32
Started ILUMYA® (tildrakizumab-asmn) in October 2019

The road to clearer skin isn't always smooth

Corey struggled with moderate-to-severe plaque psoriasis for years. He started wearing long sleeves at work to hide his plaques and avoid questions from coworkers. When his plaque psoriasis was at its worst, he couldn't sit down without leaving flakes behind. More and more, he found himself withdrawing socially. He stopped seeing friends. He rarely left the house. He even closed himself off from his family. But finding lasting clearance with ILUMYA® changed all that.

Certain activities may help reduce flares.
Here are Corey's top 3 PsO-friendly activities:

Running

Yoga

Gardening

The importance of choosing a treatment that goes the distance

Cycling through treatments can be exhausting. That's why it's good to know that with ILUMYA® (tildrakizumab-asmn), you can get your moderate-to-severe plaque psoriasis under control and keep it under control for the long haul.

Dear friend,

From my late teens all through my 20s, I struggled to find treatment for my moderate-to-severe plaque psoriasis. It started as a small spot on my scalp, but as time went on it spread to my arms and legs, and pretty much all over. Instead of enjoying my 20s, I stayed in the house more and more and saw my friends less and less. But things can get better! They did for me when I found ILUMYA®, a treatment that gave me the lasting results I was looking for. In fact, my doctor told me that most people on ILUMYA® achieve clear or almost clear skin after just 2 doses... which is exactly what happened with me. Now, as I write this 2 years later, I still have no plaques! I can hang out with my friends again - heck, I don't even think about my plaques anymore. Before I found ILUMYA®, I felt like I was fighting a losing battle with my moderate-to-severe plaque psoriasis. Now I have the upper hand on it.

Corey

The most common (≥1%) adverse reactions for ILUMYA® compared to placebo are upper respiratory infections (14% vs 12%), injection site reactions (3% vs 2%), and diarrhea (2% vs 1%).

"I went from keeping my arms and legs covered and chasing the moderate-to-severe plaque psoriasis around my body, to basically nothing. With ILUMYA®, it got better and stayed better."

Individual results may vary.

Pete M., 45
Started ILUMYA® (tildrakizumab-asmn) in June 2019

CHOOSE A TREATMENT THAT GOES THE DISTANCE

Patients see results after just 2 doses, and most achieve clear or almost clear skin in as little as 12 weeks. And 5 years into treatment, it's still going strong

CLEARER AFTER 2 DOSES

6 out of 10 people were clear or almost clear in as little as **12 weeks**.

1 YEAR AND COUNTING

8 out of 10 people who had 75% clearer skin with ILUMYA® at 7 months were still clearer after **1 year** of treatment.

STILL GOING STRONG AT 5 YEARS

9 out of 10 people who achieved clear or almost clear skin after 1 year were still seeing results **5 years into treatment**.

ILUMYA® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy (treatment using ultraviolet or UV light).

RESULTS THAT LAST

Looking for real, lasting results? Check out the before-and-after photos below. As you can see, "afters" are our specialty

BEFORE



Psoriasis plaques on the legs and above the knees

AFTER 2 DOSES

Psoriasis plaques on the legs and above the knees begin to clear after 12 weeks on ILUMYA®

AFTER 3 DOSES

Psoriasis plaques on the legs and above the knees continue to clear after 28 weeks on ILUMYA®

BEFORE

Psoriasis plaques on the arm

AFTER 2 DOSES

Psoriasis plaques on the arm begin to clear after 12 weeks on ILUMYA®

AFTER 3 DOSES

Psoriasis plaques on the arm continue to clear after 28 weeks on ILUMYA®

BEFORE

Psoriasis plaques on the back and arms

AFTER 2 DOSES

Psoriasis plaques on the back and arms begin to clear after 12 weeks on ILUMYA®

AFTER 3 DOSES

Psoriasis plaques on the back and arms continue to clear after 28 weeks on ILUMYA®

The most common (≥1%) adverse reactions for ILUMYA® (tildrakizumab-asmn) compared to placebo are upper respiratory infections (14% vs 12%), injection site reactions (3% vs 2%), and diarrhea (2% vs 1%).



"I know everyone is different and reacts differently to medication, and some patients could experience upper respiratory infections, injection site reactions, or diarrhea, but that was not my experience."

Individual results may vary.

Paul B., 70
Started ILUMYA® (tildrakizumab-asmn) in March 2019

A WELL-STUDIED SAFETY PROFILE

5 YEARS OF CONSISTENT SAFETY DATA

Across 3 clinical studies, the rates of serious infection were the same for those taking ILUMYA® and those who were given an injection without medicine in it (0.3%).

NO ROUTINE LAB MONITORING NEEDED AFTER INITIAL TESTING

Before starting ILUMYA®, your doctor may perform baseline tests and should check for tuberculosis. After checking, no routine lab monitoring is required unless your doctor feels it's necessary.

WORKS REGARDLESS OF BMI* OR WEIGHT

In clinical trials of people treated with ILUMYA®, those who had a higher BMI had similar skin clearing and risk of serious infection as those who didn't have this condition.

*Body mass index (BMI) is a measure of body fat based on height and weight.

THINGS TO CONSIDER

When choosing a treatment for moderate-to-severe plaque psoriasis, it's important to learn the potential benefits and side effects. Talk to your dermatologist to see if ILUMYA® (tildrakizumab-asmn) is the treatment you're looking for.

1. Some serious allergic reactions can occur while taking ILUMYA®. Don't use if you are allergic to ILUMYA® or any of its ingredients.

2. ILUMYA® may increase your risk of infections and lower your ability to fight them. Before starting treatment, your doctor should check for tuberculosis and infections. Call your doctor right away if you have symptoms such as fever, sweats, chills, muscle aches, or cough.

3. The most common adverse reactions for ILUMYA® compared to not taking the medication are upper respiratory infections (14% vs 12%), injection site reactions (3% vs 2%), and diarrhea (2% vs 1%). Report any negative side effects of ILUMYA® to the FDA. Visit **www.fda.gov/medwatch** or call **1-800-FDA-1088**.

4. Before receiving ILUMYA®, tell your doctor if you are pregnant or plan to become pregnant, or if you are breastfeeding or plan to breastfeed. It is not known if ILUMYA® can harm your unborn baby or pass into your breast milk.



Dr. Jerry Bagel
Director of the Psoriasis Treatment Center of New Jersey

"So you've got 150 people with **metabolic syndrome**,† and then you've got 150 people that don't have metabolic syndrome—you put them all on ILUMYA® for a year, and both groups respond equally, and there's no increase in adverse events in the metabolic syndrome group compared to the ones that are totally healthy."

†Metabolic syndromes include high blood glucose, obesity, high blood pressure, low HDL cholesterol, and high triglycerides.

The most common (≥1%) adverse reactions for ILUMYA® compared to placebo are upper respiratory infections (14% vs 12%), injection site reactions (3% vs 2%), and diarrhea (2% vs 1%).

"I'm taking care of my body on the inside for results I can see on the outside."

Individual results may vary.

Holly C., 43
Started ILUMYA® (tildrakizumab-asmn) in June 2020

RELIEF THAT'S MORE THAN SKIN DEEP

Before finding ILUMYA® to treat her moderate-to-severe plaque psoriasis, Holly struggled for 20 years to find something that worked for her. When she entered her 30s, her plaques spread and became more visible and less manageable. Her symptoms worsened as time went on, and soon she was struggling to manage her plaque psoriasis while staying focused on her roles as a mother, wife, and teacher. Finally, her dermatologist introduced her to ILUMYA® and explained that it was different from her previous treatments because it targets moderate-to-severe plaque psoriasis at the source.

Holly C.

Before ILUMYA®, I was:

- ✓ Constantly itchy
- ✓ Unable to focus
- ✓ Spending TOO much time worried about flaking

Now, I'm:

- ✓ Experiencing lasting relief
- ✓ More present and in the moment
- ✓ Participating in all my favorite hobbies again

Stuck my toes in the sand



Now that she's not always worrying about flakes, Holly is making up for lost time—with hobbies old and new.

Holly's top 5 PsO-friendly activities:

- Date nights
- Paddleboarding
- Hitting the beach
- Workout classes
- Triathlons

The most common (≥1%) adverse reactions for ILUMYA® (tildrakizumab-asmn) compared to placebo are upper respiratory infections (14% vs 12%), injection site reactions (3% vs 2%), and diarrhea (2% vs 1%).

Dosing designed for the scenic route

ILUMYA® (tildrakizumab-asmn) isn't a topical that you have to apply a few times a day. It isn't a pill that you have to take daily. ILUMYA® requires just 4 doses per year after 2 starter doses. In fact, it offers fewer doses per year than most other biologics used to treat moderate-to-severe plaque psoriasis. So now, your treatment doesn't have to be a daily, weekly, or even monthly chore.

"I OFTEN VISIT FAMILY UP IN CANADA. AND THEN I SPLIT MY TIME BETWEEN UPSTATE NEW YORK AND SOUTH CAROLINA! SO I FEEL LUCKY THAT WITH ILUMYA®, I CAN STAY ON THE ROAD WHILE STAYING ON TRACK WITH MY TREATMENT."

Individual results may vary.

Mike Q., 72
Started ILUMYA® in April 2019

DISCOVER THE DOSING ADVANTAGE OF ILUMYA®

With ILUMYA® (tildrakizumab-asmn), there are only 4 doses a year after 2 starter doses.

2 STARTER DOSES — **ONLY 4 YEARLY MAINTENANCE DOSES**

With 3 months between doses, Mike is able to put in some serious miles without worrying about missing a treatment. He knows he can drive between his 2 homes and spend quality time with his family in Canada, then head down to hit the links in South Carolina. Fore!

See how many doses the different treatment options for moderate-to-severe plaque psoriasis have over a 5-year period*

IL-23 INHIBITORS			IL-17 INHIBITORS		TNF INHIBITOR	PDE4 INHIBITOR
ILUMYA® (tildrakizumab)	**Skyrizi®** (risankizumab)	**Tremfya®** (guselkumab)	**Cosentyx®** (secukinumab)	**Taltz®** (ixekizumab)	**Humira®** (adalimumab)	**Otezla®** (apremilast)
23 INJECTIONS	23 INJECTIONS OR 46 INJECTIONS	34 INJECTIONS	138 INJECTIONS	70 INJECTIONS	131 INJECTIONS	3,649 TABLETS
ONE 100-mg injection every 12 weeks	ONE 150-mg injection OR TWO 75-mg injections every 12 weeks†	ONE 100-mg injection every 8 weeks	TWO 150-mg injections every 4 weeks‡	ONE 80-mg injection every 4 weeks§	ONE 40-mg injection every other week	ONE 30-mg tablet TWICE daily
AFTER One 100-mg injection at Weeks 0 and 4	AFTER One 150-mg injection or two 75-mg injections at Weeks 0 and 4†	AFTER One 100-mg injection at Weeks 0 and 4	AFTER Two 150-mg injections at Weeks 0, 1, 2, 3, and 4‡	AFTER Two 80-mg injections at Week 0, then 80 mg at Weeks 2, 4, 6, 8, 10, and 12§	AFTER One 80-mg injection	AFTER Initial titration doses on Days 1, 2, 3, 4, and 5

This graphic is not intended to compare the efficacy or safety of the treatments shown here. Additional considerations, aside from the dosing profile, should be taken into account before making a treatment decision. For complete product information, refer to each product's Prescribing Information.

*Indications and dosage information accessed January 2023. For complete product information, including current indications and dosing, refer to each product's Prescribing Information.

†Administered as one 150-mg single-dose prefilled pen or syringe, or two 75-mg prefilled syringes.

‡Reflects adult dosing. For some adult patients, a dose of 150 mg may be acceptable.

§Reflects adult dosing.

Indicated trademarks are registered trademarks of their respective owners.

Skyrizi® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Tremfya® is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Cosentyx® is indicated for the treatment of moderate-to-severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.

Taltz® is indicated for the treatment of patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Humira® is indicated for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Humira® should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

Otezla® is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.

The most common (≥1%) adverse reactions for ILUMYA® compared to placebo are upper respiratory infections (14% vs 12%), injection site reactions (3% vs 2%), and diarrhea (2% vs 1%).

"I'm just blown away with the science that makes ILUMYA® work."

Individual results may vary.

Nancy H., 65
Started ILUMYA® (tildrakizumab-asmn) in September 2019

MOVE PAST A SURFACE-LEVEL APPROACH TO TREATING YOUR PSORIASIS

ILUMYA® doesn't just treat the symptoms of moderate-to-severe plaque psoriasis. ILUMYA® is a biologic medicine, which means it is made using natural, living sources, such as human, plant, or animal cells. Biologics target a specific part of the immune system—rather than all of it—to block only the molecules that make psoriasis worse.

ILUMYA® is an advanced type of biologic. It blocks the IL-23 molecule, one of the key culprits behind the redness and thick plaques you see on your skin. By working on the inside, ILUMYA® can help you enjoy lasting results on the outside.

Getting serious about treatment

Nancy felt like she tried everything to get some relief. She tried a long list of ointments and topicals. Some things worked for a short period of time, but her symptoms always came back. Which is why she decided to discuss a new treatment path with a dermatologist.

PsO tip:

Diet can play a helpful or harmful role when it comes to managing plaques. Aim for foods high in antioxidants and vitamins, like this smoothie recipe Nancy swears by.

Met a horse named Apples

January 7, 2019

It's not a rash! I went to a new dermatologist today who helped me make sense of what is going on with my skin—it's plaque psoriasis. She explained that psoriasis is actually an autoimmune disease, and that my skin cells are almost attacking my body and overgrowing new cells that have nowhere to go. And that's why my skin flakes and bleeds.

And then she told me about ILUMYA®. It's a biologic medication that can balance my overactive immune system. It prevents the overgrowth of new skin cells. That's why it works for long-term clearer skin. I'm going to do my own research (I wouldn't be me if I didn't), but I've got to say, I have a good feeling about this ILUMYA®!

Nancy's Smoothie

1 ½ cups frozen blueberries
1 ½ cups frozen blackberries
1 cup spinach leaves
1 piece of ginger (size according to taste)
1 ¼ cups almond milk
½ cup plain Greek yogurt

TIP: Remove skin from ginger by scraping with a spoon

Directions:

Place all ingredients in blender (lid on!) and mix on high until smooth.
Dry ingredients can be placed in reusable zip-top bags and put in the freezer.
When ready to prepare, place in blender with the milk and yogurt and blend.

PsO Tip: Feel free to substitute whatever ingredients you have on hand, like apples, grapes, raspberries, banana, cucumber, watermelon, etc. The more vitamins, the better!

ILUMYA® (tildrakizumab-asmn) may increase your risk of infections and lower your ability to fight them. Before starting treatment, your doctor should check for tuberculosis and infections. Call your doctor right away if you have symptoms such as fever, sweats, chills, muscle aches, or cough.

DISCOVER A MORE SUPPORTIVE PATIENT SUPPORT PROGRAM

ILUMYA SUPPORT LIGHTING THE WAY® is a comprehensive patient support program that guides patients on their treatment paths with:

- Personalized support emails
- Text message reminders
- Financial assistance for those who qualify

ILUMYA SUPPORT
LIGHTING THE WAY®

Financial support that gets you going and keeps you going

ILUMYA® (tildrakizumab-asmn) has different paths to affordable treatment based on your type of insurance.

COMMERCIAL INSURANCE

$0

ILUMYA® EARLY ACCESS PROGRAM

If you have commercial insurance, you will be automatically enrolled in this program and are eligible to receive ILUMYA® for free for up to 2 years.*

$0

ILUMYA® COPAY PROGRAM

Eligible patients with commercial insurance may pay as little as $0† per dose with a copay card.

Sign up for one at ILUMYA.com/help-from-our-team/#copay-card

"When I started taking the medication, my doctor suggested that I enroll in the ILUMYA SUPPORT® program. It was an easy process to apply, and with the copay card, I only pay $5† for the injections."

Individual results may vary.

Holly C., 43
Started ILUMYA® in April 2019

*Eligibility rules apply. Patients must be commercially insured. For patients to remain eligible for the Early Access Program, providers must submit a medical and/or pharmacy prior authorization form before a patient's third dose. See full terms and conditions at ILUMYA.com/savings.

†Subject to terms and conditions. Must be enrolled in ILUMYA SUPPORT® to qualify. Not valid for patients without commercial insurance coverage or if prescription is paid for by any state- or federally funded healthcare program, including but not limited to Medicare, Medicaid, VA, DOD, or TRICARE. Available to US, Guam, Virgin Islands, or Puerto Rico residents only. See the full terms and conditions for ILUMYA SUPPORT® programs at ILUMYA.com/savings.

MEDICARE PART B

$0

MEDICARE PART B

Medicare Part B helps pay for services provided by doctors, including dermatologists, and other healthcare professionals. It also covers outpatient services needed to administer prescriptions—like infusions or injections. Because ILUMYA® (tildrakizumab-asmn) can only be administered by a healthcare professional, it's covered under Medicare Part B.

Medicare Part B coverage has a 20% cost share for ILUMYA®, but with supplemental insurance, your prescription may be covered in full.

"I'M COVERED UNDER MEDICARE PART B AND HAVE ZERO OUT-OF-POCKET COSTS FOR MY ILUMYA® TREATMENT."

Individual results may vary.

Mike Q., 72
Started ILUMYA® in April 2019

NO INSURANCE OR UNDERINSURED

ILUMYA® PATIENT ASSISTANCE PROGRAM

If you do not have enough insurance coverage or do not have insurance at all, **you may be eligible to receive ILUMYA® at no cost** through the Patient Assistance Program.

Your doctor can help you enroll in this program. If you require copay assistance for medical benefit coverage, call ILUMYA SUPPORT® at **855-4ILUMYA (855-445-8692)**.

?

READY TO GET STARTED?

- Ask your dermatologist to submit enrollment for ILUMYA SUPPORT LIGHTING THE WAY®
- Confirm coverage and qualifications for ILUMYA SUPPORT® programs
- Prepare for a call from your ILUMYA SUPPORT® team: **855-4ILUMYA (855-445-8692)**
- Schedule an appointment with your dermatologist for your first treatment

"Having a great doctor was integral on my journey to finding ILUMYA®."

Individual results may vary.

Tommy K., 74
Started ILUMYA® (tildrakizumab-asmn)
in January 2020

Find the treatment that's right for you—yes, you

There are many different types of treatments for moderate-to-severe plaque psoriasis to consider. Some of these treatments work on top of the skin, and some, like biologic medicines, work inside the body. That's why it's so important to talk with your dermatologist. Together, you can look for a plaque psoriasis treatment that works for you.

Tommy's top 3 things to talk about with your doctor:

- When did your symptoms start?
- Where are your plaques?
- What other treatments have you tried?

The most common (≥1%) adverse reactions for ILUMYA® compared to placebo are upper respiratory infections (14% vs 12%), injection site reactions (3% vs 2%), and diarrhea (2% vs 1%).

Prepare for your appointment

Answer these few questions and use this form to guide your discussion with your doctor. It could be the next step in your journey to finding lasting results.

1. What are my symptoms like? (Check all that apply)

- ☐ Scaling
- ☐ Flaking
- ☐ Redness
- ☐ Bleeding when scratched
- ☐ Itching
- ☐ Pain or discomfort

2. Where are my most frustrating symptoms?

_____

3. Treatments that I'm currently using or have used in the past: (Check all that apply)

- ☐ Prescription topicals (creams, ointments, etc)
- ☐ Oral medicines
- ☐ Light therapy (UVB phototherapy)
- ☐ Biologic injections or other injectable medicines
- ☐ Other _____

4. Concerns about treatments that I'm currently using or have used in the past:
(Check all that apply)

- ☐ I was worried about or experienced side effects
- ☐ My past treatments didn't work for me
- ☐ My treatment worked at first but eventually stopped
- ☐ Taking the medicine often was inconvenient (too many pills, injections, or applications)
- ☐ The cost of my treatment was too high
- ☐ My treatment wasn't covered under my insurance
- ☐ Other _____

5. I have the following health condition(s): (Check all that apply)

ILUMYA® (tildrakizumab-asmn) has been shown to be safe and effective in managing moderate-to-severe plaque psoriasis in patients, including in those who have these specific health conditions.

- ☐ High blood glucose
- ☐ Obesity
- ☐ High blood pressure
- ☐ Low HDL cholesterol
- ☐ High triglycerides
- ☐ I don't have any of these conditions
- ☐ Other _____

6. What am I looking for in my next treatment? (Check all that apply)

- ☐ Proof that it will work and keep working for a long time
- ☐ Information that shows it is safe
- ☐ As few doses as possible
- ☐ A treatment with a robust support program
- ☐ A treatment with an affordable copay
- ☐ A treatment that is covered by Medicare Part B
- ☐ Other _____

IMPORTANT SAFETY INFORMATION

What is ILUMYA?

ILUMYA® (tildrakizumab-asmn) is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy (treatment using ultraviolet or UV light).

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ILUMYA?

Do not use ILUMYA if you have had a severe allergic reaction to ILUMYA or any of its ingredients.

Get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

- feel faint
- trouble breathing or throat tightness
- swelling of your face, eyelids, lips, mouth, tongue or throat
- chest tightness
- skin rash

ILUMYA is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with ILUMYA and may treat you for TB before you begin treatment with ILUMYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with ILUMYA.

Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

- fever, sweats, or chills
- muscle aches
- weight loss
- cough
- warm, red, or painful skin or sores on your body different from your psoriasis
- diarrhea or stomach pain
- shortness of breath
- burning when you urinate or urinating more often than normal
- blood in your phlegm (mucus)

Before receiving ILUMYA, tell your healthcare provider about all of your medical conditions, including if you:

- have any of the conditions or symptoms listed in the section **"What is the most important information I should know about ILUMYA?"**
- have an infection that does not go away or that keeps coming back
- have TB or have been in close contact with someone with TB
- recently received or are scheduled to receive a vaccine (immunization). You should avoid receiving live vaccines during treatment with ILUMYA.
- are pregnant or plan to become pregnant. It is not known if ILUMYA can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if ILUMYA passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

It is not known if ILUMYA is safe and effective in children under 18 years of age.

What are the possible side effects of ILUMYA?

ILUMYA may cause serious side effects. See "What is the most important information I should know about ILUMYA?"

The most common side effects of ILUMYA include: upper respiratory infections, injection site reactions and diarrhea. These are not all of the possible side effects of ILUMYA. Call your doctor for medical advice about side effects.

You are encouraged to report any negative side effects of ILUMYA to FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You are also encouraged to report side effects or ADEs (adverse drug events) to our Drug Safety Department at 1-800-406-7984 or drug.safetyUSA@sunpharma.com (preferred) with as much information as available.

Please read the accompanying full Prescribing Information and Medication Guide for ILUMYA and discuss any questions with your doctor.

ILUMYA®
tildrakizumab-asmn
Injection 100 mg/mL

DISCOVER A TREATMENT THAT'S IN IT FOR THE LONG HAUL*

*Based on 5-year data.

Explore more stories from real patients on ILUMYA®

ILUMYA®
tildrakizumab-asmn
Injection 100 mg/mL

SUN PHARMA

The ILUMYA registered trademarks are the property of Sun Pharmaceutical Industries Limited. All other trademarks are the property of their respective owners.
© 2023 Sun Pharmaceutical Industries, Inc. All rights reserved.
PM-US-ILY-2130 01/2023